Nexell Therapeutics Recognized for Contributions Made to Cell Therapy Industry.Business Editors and Health/Medical Writers IRVINE, Calif.--(BUSINESS WIRE)--Jan. 12, 2000 Nexell Therapeutics Inc. (Nasdaq:NEXL) announced today that the company has been awarded Frost & Sullivan's 1999 Marketing Strategy Award, one of the Market Engineering Leadership Awards presented to companies that made a positive contribution to the growing U.S. cell therapy market. The award was announced December 20, 1999 in a press release issued by Frost & Sullivan. "Nexell's superior technology and indisputable patent protection coupled with an aggressive marketing strategy are helping the company make significant strides in the area of stem cell transplantation Stem Cell Transplantation Definition Stem cells are basic human cells that reproduce (replicate) easily, providing a continuous source of new, sometimes different types of cells. in the United States," said Viji Subramanyam, an industry analyst with Frost & Sullivan. "Nexell is in a unique position to translate these competitive advantages into sustainable market leadership as the cell therapy field continues to grow in size and complexity." In the Marketing Strategy Award citation, Frost & Sullivan also noted that Nexell had successfully consolidated the U.S. stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. selection market, following the exit of CellPro, by systematically phasing out that company's Ceprate instruments and replacing them with the Isolex(R) 300i Magnetic Cell Selection System. "We are pleased that our contribution to the cell technology field has been recognized," said William McIntosh, President and COO of Nexell Therapeutics. "Our unique technology, aggressive research program and business plan are enabling us to move rapidly toward our clinical and financial goals." Frost & Sullivan Frost & Sullivan is an international marketing consulting and training company that monitors the healthcare industry for market trends, market measures, and strategies. More information is available at www.frost.com. Nexell Therapeutics Inc. Located in Irvine, California, Nexell Therapeutics Inc. (Nasdaq:NEXL) is a cell therapy company whose mission is to put the power of the cell into the hands of healers. Nexell is developing and marketing innovative ex vivo ex vivo /ex vi·vo/ (eks´ ve´vo) outside the living body; denoting removal of an organ (e.g., the kidney) for reparative surgery, after which it is returned to the original site. cell therapies and in vitro diagnostics In vitro diagnostic (IVD) tests are medical tests conducted in a test tube, or more generally in a controlled environment outside a living organism. In vitro means in glass in Latin. for cancer, autoimmune, metabolic and genetic diseases. Nexell's lead product, the Isolex(R) 300i Magnetic Cell Selection System, is the only FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved device commercially available for the selection of hematopoietic stem cells and the removal of tumor cells from autologous autologous /au·tol·o·gous/ (aw-tol´ah-gus) related to self; belonging to the same organism. au·tol·o·gous adj. 1. peripheral blood peripheral blood Cardiology Blood circulating in the system/body as a component of aggressive cancer treatment. In addition, Nexell markets the Cytonex(TM) ICC ICC See: International Chamber of Commerce Staining Kit and an extensive line of cell therapy preparation, storage and expansion products including the Cryocyte(TM), SteriCell(R) and Lifecell(R) brands. The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 provides a "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " for certain forward-looking statements. The forward-looking statements contained in this release are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. Among the factors which could affect either Company's actual results and could cause results to differ from those contained in the forward-looking statements contained herein are: the timely commencement and success of either Company's clinical trials and other research endeavors, delays in receiving FDA or other regulatory approvals, the development of competing therapies and/or technologies, the terms of any future strategic alliances, the possible need for additional capital, and any additional factors described from time to time in either Company's periodic reports on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and 10-Q, and any prospectus describing either Company's securities. NOTE TO INVESTORS AND EDITORS: Nexell Therapeutics Inc. press releases are available on the Internet through www.nexellinc.com and through Business Wire's web site at http://www.businesswire.com. The releases are also available at no charge through Business Wire's fax-on-demand service at 800-411-8792. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion